CD19 CAR T‐Cell Therapy for Primary Mediastinal Large B‐Cell Lymphoma: A CIBMTR Analysis
American Journal of Hematology · 2025-10 · 100 (10) · 1792-1802
DOI: 10.1002/ajh.70033 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Hematology, online erschienen am 11.08.2025. Verfasst von Jordan Gauthier und 23 weiteren Autor:innen. Beteiligte Einrichtung: Fred Hutchinson Cancer Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Antigens, CD19, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Mediastinal Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Office of Naval Research, HRSA HHS.
Abstract (Originalsprache)
T cells engineered with CD19‐directed chimeric antigen receptors (CD19 CAR) T cells have become standard treatment for patients with high risk, relapsed or refractory (R/R) large B‐cell lymphomas (LBCL). However, outcomes in patients with rare subsets of LBCL, such as primary mediastinal large B‐cell lymphoma (PBMCL), have not been well characterized. The impact of prior immune checkpoint inhibitor (ICI) treatment, commonly used to treat R/R PMBCL, is also unknown. To address these gaps, we retrospectively analyzed CIBMTR registry data including PMBCL patients undergoing CD19 CAR T‐cell therapy per standard‐of‐care. A total of 135 PMBCL adults from 66 centers were included. Median age at the time of CAR T‐cell therapy was 32. Thirty‐nine patients (28.9%) had received an ICI prior to CAR T‐cell therapy. The best overall and complete response (CR) rates after CD19 CAR T‐cell therapy were 79% and 67.7%, respectively. The 2‐year progression‐free (PFS) and overall survival (OS) were 58.6% (95% CI, 49.7–67.3) and 80.8% (95% CI, 72.6–87.8), respectively. The 2‐year cumulative incidence (CI) of relapse and non‐relapse mortality (NRM) were 36% (95% CI, 27.8–44.7) and 5.4% (95% CI, 1.9–10.5), respectively. We observed grade ≥ 3 CRS and ICANS in 6.1% and 14.7%, respectively. Prior ICI exposure was associated with lower 2‐year CI of relapse (ICI‐exposed, 21.7%; ICI‐naïve, 41.6%; p = 0.03) and higher 2‐year NRM (ICI‐exposed, 11.7%; ICI‐naïve, 2.8%; p = 0.03). We could not confirm statistically different PFS ( p = 0.19) or OS ( p = 0.26) between ICI‐exposed and ICI‐naïve patients. CD19 CAR T‐cell therapy led to high rates of durable responses in PMBCL patients with low rates of severe toxicities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- University of Washington, Seattle, Washington, USA.
- Division of Biostatistics, Data Science Institute, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- Center for International Blood and Marrow Research, Milwaukee, Wisconsin, USA.
- Northwestern University Feinberg School of Medicine, and Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
- Maria Fareri Children's Hospital, Westchester Medical Center, New York Medical College, New York, New York, USA.
ORCID-Profile: Jordan Gauthier, Sherif Badawy, Mitchell S Cairo, Julio Delgado, Yago Nieto, Melhem Solh, Aung M Tun, Samuel Yamshon, Mazyar Shadman, Alex F Herrera
Förderung
- NCI NIH HHS
- Office of Naval Research
- HRSA HHS
- National Cancer Institute
- Health Resources and Services Administration
Zitieren
APA
Gauthier, J., Ahn, K. W., Patel, J., Lian, Q., Badawy, S., Cairo, M. S., Delgado, J., Grover, N., Haverkos, B., de Lima, M., Malone, A., Mussetti, A., Nieto, Y., Pawarode, A., Pearson, L., Solh, M., Sureda, A., Tun, A. M., Wudhikarn, K., …, & Herrera, A. F. (2025). CD19 CAR T‐Cell Therapy for Primary Mediastinal Large B‐Cell Lymphoma: A CIBMTR Analysis. American Journal of Hematology, 100(10), 1792-1802. https://doi.org/10.1002/ajh.70033
Vancouver
Gauthier J, Ahn KW, Patel J, Lian Q, Badawy S, Cairo MS, et al. CD19 CAR T‐Cell Therapy for Primary Mediastinal Large B‐Cell Lymphoma: A CIBMTR Analysis. American Journal of Hematology. 2025;100(10):1792-1802. doi:10.1002/ajh.70033
BibTeX
@article{Gauthier2025,
author = {Gauthier, Jordan and Ahn, Kwang W and Patel, Jinalben and Lian, Qinghua and Badawy, Sherif and Cairo, Mitchell S and Delgado, Julio and Grover, Natalie and Haverkos, Bradley and de Lima, Marcos and Malone, Adriana and Mussetti, Alberto and Nieto, Yago and Pawarode, Attaphol and Pearson, Laurie and Solh, Melhem and Sureda, Anna and Tun, Aung M and Wudhikarn, Kitsada and Yamshon, Samuel and Shadman, Mazyar and Turtle, Cameron J and Hamadani, Mehdi and Herrera, Alex F},
title = {CD19 CAR T‐Cell Therapy for Primary Mediastinal Large B‐Cell Lymphoma: A CIBMTR Analysis},
journal = {American Journal of Hematology},
year = {2025},
volume = {100},
number = {10},
pages = {1792--1802},
doi = {10.1002/ajh.70033}
}
EUVIMED